AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26417987
Drug: Biomodulatory metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomodulatory metronomic therapy
Trial: 26419191
Drug: Cadazolid 3000
RxNorm normalized name: Cadazolid
DrugBank: Cadazolid (DB11847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadazolid 3000 mg oral dose
Trial: 26419198
Drug: EV71 inactivated
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 inactivated vaccine
Trial: 26420017
Drug: Sedation or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation or analgesia (continuous infusion, intermittent doses, or both)
Trial: 26420017
Drug: Neuromuscular blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blockers
Trial: 26420017
Drug: O-SH-GA (opioids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-SH-GA (opioids, sedatives-hypnotics, general anaesthetics)
Trial: 26420235
Drug: Navitoclax 150
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 150 mg orally once daily plus erlotinib 150 mg orally once daily
Trial: 26420235
Drug: Navitoclax 150
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 150 mg/day
Trial: 26420235
Drug: Navitoclax and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax and erlotinib combination
Trial: 26420684
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (MTX, sulfasalazine, hydroxychloroquine)
Trial: 26420854
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of TA-HPV
Trial: 26421426
Drug: Combined sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days)
Trial: 26423260
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin (with potential escalation to 10 mg)
Trial: 26423374
Drug: Grazoprevir 100
RxNorm normalized name: grazoprevir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg plus Elbasvir 50 mg once daily for 12 weeks
Trial: 26423389
Drug: Whole-body insulin
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body insulin sensitivity (M value) assessed with hyperinsulinemic-euglycemic clamps
Trial: 26423734
Drug: Supplements (β-carotene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements (β-carotene, vitamin C, α-tocopherol)
Trial: 26423811
Drug: Panobinostat (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (20 mg) three times per week every other week for 8 weeks
Trial: 26423811
Drug: Panobinostat (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (20 mg)
Trial: 26423989
Drug: Maraviroc (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (600 mg twice daily)
Trial: 26427534
Drug: Increased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased insulin resistance in men
Trial: 26427534
Drug: Increased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased insulin resistance in women
Trial: 26428249
Drug: Tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol ER (100-250 mg BID)
Trial: 26428319
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) 1000 or 1500 mg/day (20 mg/kg/day, twice daily) and verapamil sustained-release tablets (120-240 mg/day)
Trial: 26428319
Drug: Xenograft studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xenograft studies with similar dosing of HU and verapamil
Trial: 26428486
Drug: Fludarabine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (30 mg/m(2)/day for 5 days on days -6 to -2) and melphalan (100 mg/m(2) on day -2)
Trial: 26428486
Drug: Fludarabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and melphalan conditioning therapy
Trial: 26428846
Drug: Daily caloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily caloric intake during ICU stay
Trial: 26429339
Drug: Clinician-supported inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-supported inpatient self-managed insulin
Trial: 26429745
Drug: Diagnosis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis and treatment strategy for obstructive sleep apnea (OSA)
Trial: 26430465
Drug: Vitamin-D group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-D group (48 μg of vitamin-D + 800 mg calcium)
Trial: 26430465
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (800 mg calcium)
Trial: 26430892
Drug: ACR <30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACR <30 mg/g (reference group)
Trial: 26432046
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg daily for the first 14 days of cycle 1 then continuously for subsequent cycles, combined with hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate, and cytarabine) every 21 days.
Trial: 26432046
Drug: Ponatinib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib maintenance 45 mg daily with vincristine and prednisone monthly for 2 years followed by ponatinib indefinitely.
Trial: 26432420
Drug: Antipsychotic treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antipsychotic treated SCZs
Trial: 26432420
Drug: Antipsychotic free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic free SCZs
Trial: 26433580
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.1 mg/m(2) (moderate impairment)
Trial: 26433580
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 0.7 mg/m(2) (severe impairment)
Trial: 26433580
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4 mg/m(2) (normal renal function)
Trial: 26433580
Drug: Simulated dose
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated dose reduction to eribulin 1.1 mg/m(2) (moderate/severe renal impairment)
Trial: 26435889
Drug: Cranial electrical
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial electrical stimulation (CES) applied via electrodes on the ear for 1 hour daily
Trial: 26436130
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg per day (initially), later reduced to 30 mg or 15 mg per day due to tolerability issues, with aspirin 81 mg daily.
Trial: 26436130
Drug: Ponatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib treatment (overall), with dose adjustments and monitoring.
Trial: 26438349
Drug: Family planning
RxNorm normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family planning and sexually transmitted infection treatment
Trial: 26438497
Drug: Ciprofloxacin plus
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin plus amoxicillin-clavulanate
Trial: 26438497
Drug: Empirical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotic combination therapy
Trial: 26439129
Drug: MVA Smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA Smallpox Vaccine (IMVAMUNE), 2 doses subcutaneously, 4 weeks apart
Trial: 26439129
Drug: MVA Smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA Smallpox Vaccine (IMVAMUNE)
Trial: 26440706
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose arsenic trioxide (0.005 mg/kg/day for 3 days) administered before chemotherapy cycles 2, 4, and 6
Trial: 26440706
Drug: Chemotherapy cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy cycles 1, 3, and 5 (baseline)
Trial: 26442234
Drug: Myofascial structural
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial structural integration therapy (n=15)
Trial: 26444282
Drug: Anakinra (ANA)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra (ANA) 100 mg daily for one year
Trial: 26445139
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin (400 mg; positive control)
Trial: 26446491
Drug: DJBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJBL treatment
Trial: 26447761
Drug: od-value thresholds
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: od-value thresholds for infarct size > 100 ml
Trial: 26447761
Drug: od-value thresholds
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: od-value thresholds for infarct size > 70 ml
Trial: 26448169
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of substance P-derived peptide FGLM-amide and IGF-1-derived peptide SSSR
Trial: 26448169
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P and insulin-like growth factor 1 (IGF-1)
Trial: 26448724
Drug: Variable dose
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dose warfarin (first dose on the night preceding surgery with subsequent target INR 2.0-2.5)
Trial: 26448724
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg daily starting 6-18 h postoperatively
Trial: 26448724
Drug: Fixed 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 1.0 mg dose warfarin daily starting 7 days preoperatively
Trial: 26448724
Drug: Fixed low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed low dose warfarin
Trial: 26448901
Drug: Oral QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QLT091001 administered once daily for 7 days
Trial: 26449224
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of temozolomide (TMZ) 150 mg/m² PO daily on days 1-5 and veliparib (ABT-888) 40 mg PO daily on days 1-7 of a 28-day cycle
Trial: 26449224
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of temozolomide (TMZ) and veliparib (ABT-888)
Trial: 26450421
Drug: Standard-dose BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose BCG SSI
Trial: 26450421
Drug: Standard-dose BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose BCG TICE
Trial: 26450421
Drug: High-dose BCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BCG SSI
Trial: 26450421
Drug: High-dose BCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BCG TICE
Trial: 26451310
Drug: Autologous or
RxNorm normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous or donor-derived T cells expressing CD19 chimeric antigen receptors (CARs) with 4-1BB and CD3ζ moiety
Trial: 26451310
Drug: Conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning chemotherapy
Trial: 26451310
Drug: No conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No conditioning chemotherapy
Trial: 26452027
Drug: cfDNA analysis
RxNorm normalized name: CFDN
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cfDNA analysis during cetuximab-based treatment
Trial: 26452027
Drug: cfDNA analysis
RxNorm normalized name: CFDN
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cfDNA analysis during cetuximab/irinotecan chemotherapy
Trial: 26452397
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of herpes zoster vaccine (ZV) administered to participants aged ≥ 70 years.
Trial: 26452397
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of herpes zoster vaccine (ZV) administered to age-matched groups (100 participants aged 50-59 years, 100 aged 60-69 years, and 200 aged ≥ 70 years).
Trial: 26452405
Drug: 14-day tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day tailored therapy based on H. pylori culture and MIC test
Trial: 26452405
Drug: 14-day EBMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day EBMT therapy
Trial: 26452405
Drug: 14-day MEA
RxNorm normalized name: MEA
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day MEA therapy
Trial: 26452561
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of one neuromuscular blocking agent (NMBA)
Trial: 26452561
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from neostigmine administration to endotracheal extubation ≥10 min
Trial: 26452561
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from last NMBA administration to endotracheal extubation ≥60 min
Trial: 26453446
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz deep rTMS (1200 pulses) over the mPFC, followed by nine additional sessions of daily rTMS
Trial: 26453479
Drug: Philips fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Philips fluid accumulation vest (FAV) used for daily monitoring of transthoracic bioimpedance for 45 days post-discharge.
Trial: 26453983
Drug: Progesterone on
RxNorm normalized name: Progesterone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone on hCG day (mean ± SD: 1.13 ± 0.69 ng/mL) among agonist-treated patients
Trial: 26453983
Drug: Progesterone on
RxNorm normalized name: Progesterone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone on hCG day (mean ± SD: 1.11 ± 0.58 ng/mL) among recombinant FSH stimulation
Trial: 26454362
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I assay, concentrations less than 5 ng/L
Trial: 26454362
Drug: Troponin concentration
RxNorm normalized name: atropine sulfate Ophthalmic Solution [Ocu-tropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin concentration of 5 ng/L or more
Trial: 26454612
Drug: Dose-Dense Paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Dense Paclitaxel, Trastuzumab, and Lapatinib (PTL)
Trial: 26457065
Drug: Natural micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural micronized progesterone vaginal tablet (FE 999913) administered twice daily
Trial: 26457225
Drug: Generic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic drugs perception assessment
Trial: 26457568
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (5 g daily for 8 weeks)
Trial: 26458184
Drug: DSM symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM symptoms (e.g., sad mood)
Trial: 26458184
Drug: Non-DSM symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-DSM symptoms (e.g., anxiety)
Trial: 26458804
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg DEN1-80E with 1.25 mg of elemental aluminum
Trial: 26458804
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg DEN1-80E with 1.25 mg of elemental aluminum
Trial: 26459220
Drug: (11)C Pittsburgh
RxNorm normalized name: Choline C 11
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (11)C Pittsburgh compound B (PIB) PET scan to quantify global amyloid deposition
Trial: 26459405
Drug: Global cardiovascular
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Global cardiovascular assessment through clinical exam, instrumental tests (electrocardiogram, echocardiogram), and biological parameters
Trial: 26459405
Drug: Biological collection
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological collection on plasma and urine
Trial: 26459812
Drug: Sunitinib or
RxNorm normalized name: sunitinib Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib or Cediranib (VEGF receptor inhibition)
Trial: 26459996
Drug: Haigis-L formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haigis-L formula
Trial: 26460303
Drug: Vemurafenib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (960 mg orally twice a day)
Trial: 26465780
Drug: Darapladib 160
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib 160 mg orally, once daily for 28 days
Trial: 26465780
Drug: Darapladib 160
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib 160 mg on Day 28
Trial: 26468043
Drug: Serologically confirmed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serologically confirmed pertussis infection (anti-PT IgG titre ⩾62·5 IU/ml)
Trial: 26471772
Drug: Incidence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidence of residual hip pain and analgesics use
Trial: 26472037
Drug: Appropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate antibiotic treatment for tracheobronchitis
Trial: 26472037
Drug: Inappropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate antibiotic treatment for tracheobronchitis
Trial: 26472751
Drug: Idelalisib 150
RxNorm normalized name: idelalisib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib 150 mg twice daily continuously for 48 weeks plus rituximab 375 mg/m(2) weekly ×8
Trial: 26473643
Drug: AZD9291 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 at doses of 20 to 80 mg/day
Trial: 26474292
Drug: Weighted endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted endurance exercise (LC) with EAA supplementation (10 g EAA, 3.6 g leucine)
Trial: 26474292
Drug: Conventional endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional endurance exercise (CE) with EAA supplementation (10 g EAA, 3.6 g leucine)
Trial: 26474521
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy followed by local excision (capecitabine 725 mg/m² twice daily, oxaliplatin 50 mg/m², radiation 50.4 Gy total)
Trial: 26476290
Drug: ombitasvir/paritaprevir/ritonavir (25/150/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ombitasvir/paritaprevir/ritonavir (25/150/100mg once daily) and dasabuvir (250mg twice daily) for 12 weeks
Trial: 26479222
Drug: Antipsychotic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic dosing regimen, specific details not available
Trial: 26479487
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) for treatment-resistant MDD and BPII depression
Trial: 26479487
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) for treatment-resistant MDD
Trial: 26479487
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) for treatment-resistant BPII depression